Evaluation of local toxic effects and outcomes for dogs undergoing marginal tumor excision with intralesional cisplatin-impregnated bead placement for treatment of soft tissue sarcomas: 62 cases (2009–2012)

• Noelle S. Bergman ^[1] ; Rebecca G. Newman ^[2] ; Bridget K. Urie ^[2] ; Anthony D. Pardo ^[3]
  1. [1] Auburn University

     Auburn University

     Estados Unidos

     
  2. [2] Department of Oncology, Pittsburgh Veterinary Specialty and Emergency Center, 807 Camp Horne Rd, Pittsburgh
  3. [3] Department of Surgery, Pittsburgh Veterinary Specialty and Emergency Center, 807 Camp Horne Rd, Pittsburgh, PA

  Mostrar afiliaciones +
• Localización: JAVMA: Journal of the American Veterinary Medical Association, ISSN-e 0003-1488, Vol. 248, Nº. 10, 2016, págs. 1148-1156
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • OBJECTIVE To evaluate outcomes for dogs following marginal tumor excision and intralesional placement of cisplatin-impregnated beads for the treatment of cutaneous or subcutaneous soft tissue sarcomas (STSs) and assess local toxic effects of cisplatin-impregnated beads in these patients.

    DESIGN Retrospective case series.

    ANIMALS 62 client-owned dogs.

    PROCEDURES Medical records were reviewed to identify dogs with STSs treated with marginal excision and intralesional placement of cisplatin-impregnated beads. Patient signalment; tumor location, type, and grade; dates of tumor resection and bead placement; number of beads placed; and concurrent treatments were recorded. Data regarding toxicosis at the bead site (up to the time of suture removal) and tumor recurrence were collected; variables of interest were evaluated for associations with these outcomes, and systemic adverse effects (if any) were recorded.

    RESULTS 24 of 51 (47%) evaluated dogs had toxicosis at bead placement sites (classified as mild [n = 12] or moderate [10] in most). Fifteen of 51 (29%) tumors recurred. Median disease-free interval was not reached for dogs with grade 1 and 2 STSs, whereas that for dogs with grade 3 STSs was 148 days. Disease-free survival rates of dogs with grade 1 and 2 tumors at 1, 2, and 3 years were 88%, 75%, and 64%, respectively. One dog was treated for presumptive systemic toxicosis but recovered with medical treatment.

    CONCLUSIONS AND CLINICAL RELEVANCE Cisplatin-impregnated beads were generally well tolerated; good results were achieved for dogs with grade 1 or 2 STSs. Prospective, controlled studies are needed to determine efficacy of this treatment for preventing recurrence of marginally excised STSs in dogs.